NATCO Pharma Limited

NSE:NATCOPHARM.NS

1407.15 (INR) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q32014 Q22014 Q12013 Q42013 Q32013 Q22013 Q12012 Q42012 Q32012 Q22012 Q12011 Q42011 Q32011 Q22011 Q1
Revenue 13,62610,6837,58610,31411,4058,9794,9254,3218,8465,5695,6053,7724,103-3053,5528,0225,6344,2764,8224,8574,9234,2305,5675,4355,3867,6785,6224,2674,2815,7786,428.64,152.12,977.13,9442,631.22,227.72,156.92,350.0331,842.72,090.61,904.82,171.2871,861.81,629.11,645.41,837.481,577.81,803.21,344.71,618.3641,293.11,266.5
Cost of Revenue 3,6633,4061,6222,1581,9602,5841,1541,0581,4774,1699309257911,5108311,9491,7892,2339151,1927601,7471,0509498731,2306581,1291,0941,1722,054.21,837.6926.9998921.5673.6698.4903.877630.5644.1656.51,053.163579.1578.6547890.456668.1665.8531.7914.798516.2478.3
Gross Profit 9,9637,2775,9648,1569,4456,3953,7713,2637,3691,4004,6752,8473,312-1,8152,7216,0733,8452,0433,9073,6654,1632,4834,5174,4864,5136,4484,9643,1383,1874,6064,374.42,314.52,050.22,9461,709.71,554.11,458.51,446.1561,212.21,446.51,248.31,118.1231,282.71,050.51,098.4947.024909.71,137.4813703.565776.9788.2
Gross Profit Ratio 0.7310.6810.7860.7910.8280.7120.7660.7550.8330.2510.8340.7550.8075.9510.7660.7570.6820.4780.810.7550.8460.5870.8110.8250.8380.840.8830.7350.7440.7970.680.5570.6890.7470.650.6980.6760.6150.6580.6920.6550.5150.6890.6450.6680.5150.5770.6310.6050.4350.6010.622
Reseach & Development Expenses 000008920001,6820001,4250001,5430001,8760001,279020009300161000000000142.852000146.336000000
General & Administrative Expenses 000001,1580001,7720008490009040008730000000000000000000292.492000160.665000000
Selling & Marketing Expenses 000006570003260002110009360008470000000000000000000261.604000148.207000000
SG&A 2,3562,8592,0642,3522,2731,8151,6561,2071,8972,0982,4751,0501,1331,0601,0141,2379521,8409781,0249321,7209339268871,2677887486311,086.7560604.2497.8615.5469.5430.4402.6290.569332.9336.9318.31,027.213297.6263.3258.9700.678244.73100000
Other Expenses 4814203702941973,4143,1272,7273,8121,752302380170-642308257187-810308332210-9722334003592011145534-6361.5526.5275.14129.2121.380.2-394.208111.9101.7194.8-400.455171.8163.179.7-299.904198.3744.363.7-241.29494.7512.1
Operating Expenses 2,3562,8593,7254,0124,6003,4143,1272,7273,8121,7524,0172,4892,552-2,3902,1943,5962,4149812,8742,5412,4701,1752,6402,4832,5212,7952,2712,0791,9702,3302,209.71,902.11,632.72,1371,305.81,196.61,072.2741.664896.91,039.5967.6461.165979.6833.7769.4427.529659.7744.3613.4302.308597.4512.1
Operating Income 7,6074,4182,6094,4385,0423,2718527413,900-4749603587605755272,4771,4311,0621,0331,1241,6931,3081,8772,0031,9923,6532,6931,0591,2172,2762,164.7412.4417.5809403.9357.5386.3704.492315.3407280.7656.958303.1216.8329519.495250393.1199.6401.257179.5276.1
Operating Income Ratio 0.5580.4140.3440.430.4420.3640.1730.1710.441-0.0850.1710.0950.185-1.8850.1480.3090.2540.2480.2140.2310.3440.3090.3370.3690.370.4760.4790.2480.2840.3940.3370.0990.140.2050.1540.160.1790.30.1710.1950.1470.3030.1630.1330.20.2830.1580.2180.1480.2480.1390.218
Total Other Income Expenses Net 429358-46-42-42-27-38-38-42-22-503401501322742301501052552701452161703503311717113-5-70315.1484.5243.1-3293.444.7-0.6-399.52-124.529.5129.2-338.6979.662.9-19.9-303.20268.4-120.117-214.33936.6-61.2
Income Before Tax 8,0364,7762,5634,3965,0003,2448147033,858-4969106989107078012,7071,5811,1671,2881,3941,8381,5242,0472,3532,3233,8242,7641,0721,2122,2062,479.8896.9660.6777497.3402.2385.7304.972190.8436.5409.9318.268382.7279.7309.1216.293318.4273216.6186.918216.1214.9
Income Before Tax Ratio 0.590.4470.3380.4260.4380.3610.1650.1630.436-0.0890.1620.1850.222-2.3180.2260.3370.2810.2730.2670.2870.3730.360.3680.4330.4310.4980.4920.2510.2830.3820.3860.2160.2220.1970.1890.1810.1790.130.1040.2090.2150.1470.2060.1720.1880.1180.2020.1510.1610.1150.1670.17
Income Tax Expense 1,351913436706797486191135654910647160177167668360235244217410320454537512827590228275442531.4234.7186.3141130.6110.4110.3-226.59854.2124.187.863.4108.237.1101.4132.064106.177.149.161.84850.458.3
Net Income 6,6853,8632,1273,6904,2032,7586235683,204-5058046517505306272,0241,2289411,0451,1901,4321,2081,5951,8251,8162,9992,1758489401,7671,951665475628369.3292.9280.7544.458143.4323.7334.6240.143298.8269.2217.8113.291225.9209.9170.7126.483170159.4
Net Income Ratio 0.4910.3620.280.3580.3690.3070.1260.1310.362-0.0910.1430.1730.183-1.7380.1770.2520.2180.220.2170.2450.2910.2860.2870.3360.3370.3910.3870.1990.220.3060.3030.160.160.1590.140.1310.130.2320.0780.1550.1760.1110.160.1650.1320.0620.1430.1160.1270.0780.1310.126
EPS 37.3221.5611.8820.6123.2615.113.413.1117.56-2.774.413.574.112.913.4411.126.745.175.756.557.876.648.659.899.8416.2612.294.825.5910.111.183.792.743.862.131.811.72.990.871.962.021.321.871.721.390.621.441.351.10.691.181.13
EPS Diluted 37.3221.5611.8820.6123.2615.113.413.1117.55-2.764.43.574.112.913.4311.096.735.175.736.537.856.648.639.869.8216.2112.254.825.5810.0911.163.782.733.852.131.811.72.990.871.962.021.321.871.721.390.621.441.351.10.691.181.13
EBITDA 8,0484,9733,0514,8745,4773,6811,2671,1584,296-931,3201,0851,2681,0011,1333,0211,8981,3611,5951,6752,1231,7622,3172,6052,5354,0342,9791,2741,4012,4052,663.11,079.9824.1936666.3605.6592.9489.701549620.4586.9448.707551.9454.6481.8344.083511.7444.1307.6222.717315316.3
EBITDA Ratio 0.5910.4660.4020.4730.480.410.2570.2680.486-0.0170.2360.2880.309-3.2820.3190.3770.3370.3180.3310.3450.4310.4170.4160.4790.4710.5250.530.2990.3270.4160.4140.260.2770.2370.2530.2720.2750.2080.2980.2970.3080.2070.2960.2790.2930.1870.3240.2460.2290.1380.2440.25